Valuation Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.86 USD | +4.39% |
|
-2.98% | +8.74% |
| Jul. 20 | Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026 | RE |
| Jul. 07 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
Company Valuation: Scholar Rock Holding Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 872.1 | 467.6 | 1,356 | 4,046 | 4,493 | 5,494 | - | - |
| Change | - | -46.39% | 190.08% | 198.32% | 11.06% | 22.27% | - | - |
| Enterprise Value (EV) 1 | 709.3 | 414 | 1,304 | 3,918 | 4,270 | 5,192 | 5,139 | 5,202 |
| Change | - | -41.63% | 215.07% | 200.38% | 8.97% | 21.61% | -1.03% | 1.23% |
| P/E | -6.92x | -4x | -9.45x | -17.5x | -13.4x | -14.4x | -18x | -29.7x |
| PBR | 5.3x | 2.07x | 6.96x | 11x | 20.6x | 22.3x | 21.7x | 26.9x |
| PEG | - | 0.1x | 0.8x | -0.7x | -0.4x | 4.25x | 0.9x | 0.8x |
| Capitalization / Revenue | 46.3x | 14.1x | - | - | - | 844x | 36.8x | 15.7x |
| EV / Revenue | 37.7x | 12.5x | - | - | - | 797x | 34.4x | 14.9x |
| EV / EBITDA | -5.57x | - | - | - | -11.1x | -12.2x | -17.6x | -53.3x |
| EV / EBIT | -5.46x | -3.08x | -7.62x | -15.5x | -11.1x | -12.1x | -15.2x | -28.1x |
| EV / FCF | -5.37x | -3.1x | -8.98x | -19.5x | -14.2x | -16x | -23.1x | -58.3x |
| FCF Yield | -18.6% | -32.3% | -11.1% | -5.13% | -7.04% | -6.27% | -4.33% | -1.72% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | -3.179 | -2.552 | -1.546 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.82 | 33.19 | - | - | - | 6.512 | 149.5 | 350.1 |
| EBITDA 1 | -127.3 | - | - | - | -383 | -426.8 | -292.4 | -97.64 |
| EBIT 1 | -129.9 | -134.4 | -171.3 | -252.1 | -384.6 | -430.4 | -337.6 | -185.1 |
| Net income 1 | -131.8 | -134.5 | -165.8 | -246.3 | -377.9 | -409.7 | -356.3 | -209.9 |
| Net Debt 1 | -162.8 | -53.53 | -51.84 | -127.7 | -223.8 | -302.1 | -355.6 | -292.4 |
| Reference price 2 | 24.84 | 9.05 | 18.80 | 43.22 | 44.05 | 45.85 | 45.85 | 45.85 |
| Nbr of stocks (in thousands) | 35,108 | 51,663 | 72,143 | 93,615 | 102,007 | 119,828 | - | - |
| Announcement Date | 3/7/22 | 3/7/23 | 3/19/24 | 2/27/25 | 3/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -14.42x | 797.32x | -12.17x | -.--% | 5.49B | |
| 17.93x | 5.93x | 12.15x | 1.71% | 56.7B | |
| 30.64x | 7.55x | 23.21x | 0.05% | 51.97B | |
| -18.24x | 4.35x | -7.62x | -.--% | 23.33B | |
| -37.99x | 12.2x | -35.93x | -.--% | 21.34B | |
| 24.11x | 4.7x | 15.27x | -.--% | 17.44B | |
| 44.73x | 18.1x | 46.61x | 0.08% | 14.77B | |
| 17.37x | 5.01x | 11.7x | -.--% | 13.84B | |
| -26.49x | 25.4x | -31.82x | -.--% | 12.12B | |
| -76.33x | 6.97x | -57.58x | -.--% | 11.14B | |
| Average | -3.87x | 88.75x | -3.62x | 0.18% | 22.81B | |
| Weighted average by Cap. | 6.33x | 27.51x | 4.27x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SRRK Stock
- Valuation Scholar Rock Holding Corporation
Select your edition
All financial news and data tailored to specific country editions
